Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]

Kelly Bailey, Carrye Cost, Ian Davis, Julia Glade-Bender, Patrick Grohar, Peter Houghton, Michael Isakoff, Elizabeth Stewart, Nadia Laack, Jason Yustein, Damon Reed, Katherine Janeway, Richard Gorlick, Stephen Lessnick, Steven DuBois, Pooja Hingorani

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.

Original languageEnglish (US)
Article number493
JournalF1000Research
Volume8
DOIs
StatePublished - 2019

Keywords

  • Clinical trials
  • Ewing sarcoma
  • Metastasis
  • Relapse
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]'. Together they form a unique fingerprint.

  • Cite this

    Bailey, K., Cost, C., Davis, I., Glade-Bender, J., Grohar, P., Houghton, P., Isakoff, M., Stewart, E., Laack, N., Yustein, J., Reed, D., Janeway, K., Gorlick, R., Lessnick, S., DuBois, S., & Hingorani, P. (2019). Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]. F1000Research, 8, [493]. https://doi.org/10.12688/f1000research.18139.1